Wealth rating firm Forbes states that most billionaires worldwide fall within the age range of 50 to 79. However, 12% of billionaires are younger than this range, achieving billionaire status by the ...

Co-production deals with adalimumab biosimilar manufacturers and PBMs have increased biosimilar adoption, but this ...

The National Comprehensive Cancer Network® (NCCN®) and the NCCN Foundation® proudly announce four recipients for the 2025 NCCN Foundation Young Investigator Awards (YIA). These awards provide ...

The AI in Life Science Market is anticipated to experience a remarkable compound annual growth rate (CAGR) of around 25% in ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

NBE Therapeutics (NBE) a wholly owned subsidiary of Boehringer Ingelheim, officially opened its new ADC R&D facility in Basel ...

New evidence suggests that factors other than the percentage of weight loss should be considered when determining the success ...

Kanazawa University and colleagues have developed a promising new approach to cancer treatment. By using tiny, naturally occurring particles called extracellular vesicles (EVs), they ...

With concerns mounting and speculation swirling, the particulars of President Donald Trump’s much-touted “Liberation Day” ...

According to Forbes, nearly 75% of the world’s dollar billionaires are between 50 and 79 years old, and just 12% are under 50 ...

With counterfeit drugs making up 30% of global sales, regulators are tightening serialisation and labelling rules to secure ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...